Opioid Use Disorder (OUD) Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of AZD4041 in Healthy Adult Subjects
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, MAD study in healthy male and female adult subjects. The study will include up to 48 subjects (12 subjects per cohort) who will be randomized 9:3 to active drug or placebo. Each cohort will receive AZD4041 or placebo in a MAD study. A sequential cohort MAD design will be employed to assure that higher doses are administered to healthy subjects only after lower doses have demonstrated an acceptable safety profile. The total study duration will be up to 59 days (including Screening) per subject.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04111939 -
HEALing Communities Study
|
N/A | |
| Withdrawn |
NCT03547882 -
Addiction Treatment in Primary Care Expansion
|
||
| Recruiting |
NCT04464980 -
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
|
Phase 2 | |
| Completed |
NCT05233085 -
A Safety Study of AZD4041 in Healthy Participants
|
Phase 1 |